Browse > Article
http://dx.doi.org/10.4333/KPS.2010.40.S.075

Nano-sized Drug Carriers and Key Factors for Lymphatic Delivery  

Choi, Ji-Hoon (College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University)
Lee, Yong-Bok (College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University)
Publication Information
Journal of Pharmaceutical Investigation / v.40, no.spc, 2010 , pp. 75-82 More about this Journal
Abstract
Specific diseases like cancer and acquired immune deficiency syndrome (AIDS) occur at various organs including lymphatics and spread through lymphatic system. Thus, if therapeutic agents for such diseases are more distributed or targeted to lymphatic system, we can obtain several advantages like reduction of systemic side effect and increase of efficacy. For these reasons, much interest has been focused on the nature of lymphatics and a lot of studies for lymphatic delivery of drugs have been carried out. Because lymphatics consist of single layer endothelium and have high permeability compared with blood capillaries, especially, the studies using nano-sized carriers have been performed. Polymeric nano-particle, liposome, and lipid-based vehicle have been adopted for lymphatic delivery as carriers. According to the administration route and the kind of carrier, the extent of lymphatic delivery efficiency of nano-sized carriers has been changed and influenced by several factors such as size, charge, hydrophobicity and surface feature of carrier. In this review, we summarized the key factors which affect lymphatic uptake and the major features of carriers for achieving the lymphatic delivery. Lymphatic delivery of drug using nano-sized carriers has many fold improved ability of lymphatic delivery compared with that of conventional dosage forms, but it has not shown whole lymph selectivity yet. Even though nano-sized carriers still have the potential and worth to study as lymphatic drug delivery technology as before, full understanding of delivery mechanism and influencing factors, and setting of pharmacokinetic model are required for more ideal lymphatic delivery of drug.
Keywords
Lymphatic system; Nano-sized carriers; Lymphatic delivery;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Supersaxo, A., Hein, W.R., Steffen, H., 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7, 167-169.   DOI
2 Oussoren, C., Zuidema, J., Crommelin, D.J., Storm, G., 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328, 261-272.   DOI
3 Paliwal, R., Paliwal, S. R., Mishra, N., Mehta, A., Vyas, S.P., 2009. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm 380, 181-188.   DOI
4 Parker, R. J., Hartman, K.D., Sieber, S.M., 1981. Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res 41, 1311-1317.
5 Patel, H.M., Boodle, K.M., Vaughan-Jones, R., 1984. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta 801, 76-86.   DOI   ScienceOn
6 Pepper, M.S., Skobe, M., 2003. Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol 163, 209-213.   DOI
7 Rao, D.A., Forrest, M.L., Alani, A.W., Kwon, G.S., Robinson, J. R., 2010. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 99, 2018-2031.   DOI
8 Senior, J.H., 1987. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3, 123-193.
9 Shin, S.B., Cho, H.Y., Kim, D.D., Choi, H.G., Lee, Y.B., 2010. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 74, 164-171.   DOI
10 Singh, R., Lillard, J.W., Jr., 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86, 215-223.   DOI
11 Allen, T., Hansen, C., Guo, L., 1993. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochimica et Biophysica Acta (BBA)-Biomembranes 1150, 9-16.   DOI
12 Allen, T., Moase, E., 1996. Therapeutic opportunities for targeted liposomal drug delivery. Advanced drug delivery reviews 21, 117-133.   DOI
13 Cavanagh, L.L., Von Andrian, U.H., 2002. Travellers in many guises: the origins and destinations of dendritic cells. Immunol Cell Biol 80, 448-462.   DOI
14 Chambers, A.F., Groom, A.C., Macdonald, I.C., 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.   DOI
15 Swartz, M.A., 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50, 3-20.   DOI
16 Takakura, Y., Atsumi, R., Hashida, M., Sezaki, H., 1987. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. International Journal of Pharmaceutics 37, 145-154.   DOI
17 Takakura, Y., Matsumoto, S., Hashida, M., Sezaki, H., 1984. Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res 44, 2505-2510.
18 Tanis, P.J., Nieweg, O.E., Valdes Olmos, R.A., Kroon, B.B., 2001. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 192, 399-409.   DOI
19 Trevaskis, N.L., Charman, W.N., Porter, C.J., 2008. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60, 702-716.   DOI
20 Trevaskis, N.L., Porter, C.J., Charman, W.N., 2006. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther 316, 881-891.
21 Tumer, A., Kirby, C., Senior, J., Gregoriadis, G., 1983. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. Biochim Biophys Acta 760, 119-125.   DOI   ScienceOn
22 Xie, Y., Bagby, T.R., Cohen, M.S., Forrest, M.L., 2009. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv 6, 785-792.   DOI
23 Oussoren, C., Storm, G., 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50, 143-156.   DOI
24 Kohli, K., Chopra, S., Dhar, D., Arora, S., Khar, R.K., 2010. Selfemulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today
25 Karajgi, J.S., Vyas, S.P., 1994. A lymphotropic colloidal carrier system for diethylcarbamazine: preparation and performance evaluation. J Microencapsul 11, 539-545.   DOI
26 Kaur, C.D., Nahar, M., Jain, N.K., 2008. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 16, 798-805.   DOI
27 Kim, C.K., Han, J.H., 1995. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 12, 437-446.   DOI
28 Ling, S.S., Magosso, E., Khan, N.A., Yuen, K.H., Barker, S.A., 2006. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 32, 335-345.   DOI
29 Luo, G., Yu, X., Jin, C., Yang, F., Fu, D., Long, J., Xu, J., Zhan, C., and Lu, W., 2010. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 385, 150-156.   DOI
30 Muller, C.D., Schuber, F., 1989. Neo-mannosylated liposomes: synthesis and interaction with mouse Kupffer cells and resident peritoneal macrophages. Biochim Biophys Acta 986, 97-105.   DOI
31 Nankervis, R., Davis, S., Day, N., Shaw, P., 1996. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. International Journal of Pharmaceutics 130, 57-64.   DOI
32 O'driscoll, C.M., 2002. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15, 405-415.   DOI
33 Garg, M., Jain, N.K., 2006. Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J Drug Target 14, 1-11.   DOI
34 Charman, W., Porter, C., 1996. Lipophilic prodrugs designed for intestinal lymphatic transport. Advanced drug delivery reviews 19, 149-169.   DOI
35 Charman, W., Stella, V., 1986. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. International Journal of Pharmaceutics 33, 165-172.   DOI
36 Feng, L., Zhang, L., Liu, M., Yan, Z., Wang, C., Gu, B., Liu, Y., Wei, G., Zhong, G., Lu, W., 2010. Roles of dextrans on improving lymphatic drainage for liposomal drug delivery system. J Drug Target 18, 168-178.   DOI
37 Gershkovich, P., Hoffman, A., 2005. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 26, 394-404.   DOI
38 Gursoy, R.N., Benita, S., 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58, 173-182.   DOI
39 Hawley, A.E., Illum, L., Davis, S.S., 1997. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 14, 657-661.   DOI
40 Immordino, M.L., Dosio, F., Cattel, L., 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1, 297-315.   DOI
41 Jurisic, G., Detmar, M., 2009. Lymphatic endothelium in health and disease. Cell Tissue Res 335, 97-108.   DOI